693 results about "Rheumatic arteritis" patented technology

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.

The invention relates to the technical field of digital health, in particular to a personalized rehabilitation exercise method for rheumatoid arthritis patients based on a BCW theory, which comprises the following steps: acquiring joint angle change and calculating a pain delay response coefficient, detecting fluctuation of supporting force and stabilizing force to obtain a joint load tolerance value, analyzing respiratory coordination to generate a respiratory coordination index, and performing rehabilitation training on the respiratory coordination index. The method comprises the steps that a joint angle sensor and pain intensity data are analyzed, a BCW capacity factor weight value is generated in a weighted mode, a fuzzy control algorithm is input to conduct hierarchical mapping adjustment on action amplitude frequency and rest intervals, and exercise adaptability feedback data are generated through monitoring completion degree and pain feedback. The exercise intensity is dynamically adjusted in real time through a data model, a personalized rehabilitation scheme is automatically optimized, the problems that subjective feedback is relied on, and physiological changes cannot be responded in time are solved, more accurate exercise amount adjustment is provided, the situation that the joint burden is increased due to improper exercise intensity is avoided, and the rehabilitation process is effectively promoted.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention discloses a risk assessment method for rheumatoid arthritis accompanied with cognitive impairment based on big data, and belongs to the field of data feature extraction, and the method specifically comprises the steps: carrying out the unified calling of collected clinical, laboratory and iconography features as an original feature set, and completing the preprocessing through multiple interpolation and Z-score standardization; inputting the original feature set into a self-attention network, and generating interaction feature representation for mining high-order interaction; low-dimensional potential feature vectors are compressed, and combined training is carried out through reconstruction and discriminant loss; inputting the potential feature vectors into an XGBoost model, and screening out a preliminary candidate feature subset; performing global and local importance evaluation on the candidate feature subsets by adopting SHAP, and iteratively rejecting features of which the contribution degrees are lower than a threshold value epsilon until the final feature subset is stable; and respectively inputting the final feature subsets into the simplified ResNet and LightGBM to obtain two groups of risk scores, and then generating a fusion risk score through weighted fusion.

The invention provides a rheumatoid arthritis patient low muscle quality risk prediction method based on an uncertainty perception stacked meta-learning structure, and belongs to the technical field of machine learning. The method comprises the following steps: acquiring a rheumatoid arthritis data set; constructing a base learner set comprising a table Transform class network and a gradient boosting tree class model; splicing the out-of-fold prediction probabilities of all the base learners and the statistics thereof to form a meta-feature matrix; taking the meta feature matrix as input, and constructing and training a meta learner comprising a spectrum normalization multilayer perceptron and a random feature Gaussian process output layer; collecting to-be-detected data, inputting the to-be-detected data into the trained base learner set and the trained meta learner in sequence, and performing temperature scaling and beta-calibration on a prediction result; and taking the calibrated prediction probability as a final prediction result. Through multi-source data fusion, the defects of an existing model in the aspects of practicability, probability reliability and the like are overcome.

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention relates to the technical field of microbiology, in particular to application of Eubacterium rectum to preparation of a preparation for relieving rheumatoid arthritis. It is found for the first time that Eubacterium rectum can improve joint inflammation and bone destruction of mice by adjusting immune tolerance, and the Eubacterium rectum is applied to development of microbial preparations containing Eubacterium rectum so as to improve intestinal flora of rheumatoid arthritis patients, so that the effects of adjusting immunity and relieving rheumatoid arthritis conditions are achieved.

The invention relates to the technical field of health monitoring, in particular to a rheumatoid arthritis patient hand function rehabilitation effect evaluation system in combination with a BCW theory, and the system comprises a behavior analysis module, a capability extraction module, an opportunity evaluation module, an effect analysis module and a stage optimization module. According to the method, the hand track and task records are collected, the execution rate and the duration are extracted and subjected to normalization fitting, a dynamic behavior portrait is constructed, principal component extraction is conducted in combination with the flexion and extension angle and the electromyographic signals, high-weight capacity characteristics are generated, the time difference between triggering and reaction of the device is monitored, the response delay change rate is calculated, and the task time is compared; according to the method, the relation between external stimulation and capability activation is revealed, behavior, capability and response characteristics are fused to construct an effect curved surface, the stability and gradient direction are analyzed, rehabilitation effect three-dimensional quantification and progress trend presentation are achieved, differentiated rehabilitation paths are adapted, and evaluation precision and regulation and control capability are improved.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

The invention provides a nitric oxide fluorescent probe with aggregation-induced emission characteristics and a preparation method and application thereof. The structural formula of the nitric oxide fluorescent probe is shown in the specification. The nitric oxide fluorescent probe provided by the invention is high in detection sensitivity, high in response speed, excellent in NO selectivity and AIE characteristic, wide in application range, not only suitable for liquid-phase and gas-phase NO detection, but also capable of realizing high-efficiency real-time detection of NO in body fluid, cells and living body samples, and wide in application prospect. The method can be used for diagnosis of diseases such as inflammation (rheumatoid arthritis), tumor microenvironment and the like, high-throughput drug screening and environment monitoring.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The invention provides an early-stage intelligent diagnosis method for rheumatoid arthritis based on a multi-modal medical image and deep learning, and the method comprises the steps: carrying out the image cleaning and standardization, automatic bone joint positioning and segmentation, and quality control of a multi-modal original data set, and obtaining a joint slice library; performing intra-modal self-supervised pre-training and cross-modal alignment representation, and then performing focus level detection and quantification to obtain a lesion feature vector of each joint; performing joint diagram construction and quality perception multi-modal fusion to obtain fusion feature representation, and performing weak supervision multi-instance learning and multi-task loss calculation based on the fusion feature representation to obtain an uncalibrated model; and carrying out model calibration and explainable output to obtain an intelligent diagnosis model. According to the method, the diagnosis time point can be advanced to the reversible inflammation stage, interpretable evidence of patient-level decision and joint-level quantification is provided, the engineering feasibility of small samples and multi-center generalization is considered, and the method has high clinical transformation potential.

The invention relates to a pharmaceutical composition, the pharmaceutical composition contains an effective amount of active ingredients and pharmaceutically acceptable auxiliary materials, and the active ingredients comprise mangiferin, glycyrrhizic acid and cinnamic acid. The invention also relates to an application of the pharmaceutical composition in preparation of a medicine for treating or improving diseases, wherein the diseases are rheumatoid arthritis; the pharmaceutical composition contains an effective amount of active ingredients, and the active ingredients comprise mangiferin, glycyrrhizic acid and cinnamic acid. The pharmaceutical composition disclosed by the invention can be used for remarkably improving the severity of rheumatoid arthritis of a rat suffering from adjuvant-induced rheumatoid arthritis. And almost no adverse reaction or side effect exists.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

1. The name of this design product: Rehabilitation training equipment. 2. Purpose of this design product: used for the rehabilitation of rheumatoid arthritis. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.